[Ip-health] Ekathimerini interview with James Love on delinkage and access to medicines

Thiru Balasubramaniam thiru at keionline.org
Wed May 3 03:48:35 PDT 2017


The key idea behind the battle James Love has been waging for the past four
decades on five continents is that mass producing medicines is cheap. The
real cost lies in the research and clinical trials behind the discovery and
production of each new drug. But if society were to find a way to reward
public laboratories and private companies for research and innovation, and
then allow any company to mass produce the drug, this would significantly
reduce the cost and bring huge benefits to the public health system

Love, who is director of Knowledge Ecology International – a
nongovernmental organization focused mainly on knowledge management and
governance, including intellectual property policy – and also works as an
adviser for various United Nations agencies, argues that the delinkage of
the cost of research from the final cost of a drug is an unavoidable change
in the business model.

Love was in Athens recently, as a guest of the Hellenic Organization of
Industrial Property (OBI), whose director general, Dr Ioannis Kaplanis,
told Kathimerini that the expert’s recommendations on compulsory licensing,
open innovation and patent pools are currently under discussion with the
Greek Health and Welfare ministries.


More information about the Ip-health mailing list